Neisseria meningitidis is a Gram-negative, encapsulated diplococcal bacterium and is the causative agent for invasive meningococcal disease. Although relatively rare around the globe, invasive meningococcal disease is widely feared because of its high mortality rate even in otherwise healthy individuals. The onset of invasive meningococcal disease typically begins within three to seven days of infection, but can occur as early as one day after infection. If left untreated, meningococcal disease progresses rapidly. Even with appropriate treatment, up to 10% of all cases still result in death within 24 to 48 hours of symptom onset. This rapid onset and progression of the disease emphasizes the need for a prophylactic approach by vaccination.
Pharmaceutical companies have developed vaccines addressing the most urgent medical needs based on clinical efficacy and epidemiology. The resulting vaccines can be divided into three categories, although other and finer segmentations can be made. These three categories include monovalent vaccines targeting serogroup C (MenC vaccines), vaccines protecting against most serogroup B strains (MenB vaccines), and tetravalent vaccines protecting against serogroups A, C, W, and Y (MenACWY vaccines). While the MenB vaccines use recombinant proteins as antigens, all other meningococcal vaccines are based on the polysaccharide capsules of the various serogroups.
Key Questions Answered
- Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the meningococcal vaccine marketplace.
- What will be the effect of recent and upcoming changes in national immunization schedules?
- How will the new first-in-class vaccine covering all main serogroups (MenABCWY) be received in the different markets?
- What research and development (R&D) strategies will companies leverage to compete in the future meningococcal vaccine marketplace?
- Which patient population(s) are most likely to be targeted for vaccines against serogroup B and the pentavalent MenABCWY pipeline vaccine?
- GlobalData projects the Meningococcal Vaccine Market in the US, 5EU, Japan, and Brazil to grow from approximately $1.1bn in 2015 to $1.8bn in 2025, at a compound annual growth rate (CAGR) of 5.4%.This growth across the 8MM will primarily be driven by the introduction of additional meningococcal vaccines into the national routine infant and adolescent vaccination schedules in some 5EU countries. Further growth will be the result of the launch of a pentavalent MenABCWY vaccine during the forecast period while the commercial meningococcal vaccine markets in Brazil and Japan will experience a decline at a negative CAGR of 1.8% and 0.9% respectively.
- With most countries in the 8MM using serogroup B vaccines only for individuals at high risk of contracting meningococcal disease, the routine application of these protein-based vaccines is seen as the major unmet need to be addressed in the oncoming years.
- GlobalData anticipates that opportunities will center on the improvement of vaccine long-term efficacy whilst addressing the cost effectiveness concerns voiced by various governmental institutions.
- Overview of meningococcal disease, including epidemiology, etiology, pathophysiology, regional serogroup distribution, as well current routine meningococcal vaccine recommendations of all 8MM covered.
- Topline meningococcal vaccine market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the meningococcal vaccine market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
- Analysis of the current and future market competition in the global meningococcal vaccine marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Get Exclusive Discount on this Report@ https://www.wiseguyreports.com/check-discount/643855-pharmapoint-meningococcal-vaccines-global-drug-forecast-and-market-analysis-to-2025
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global meningococcal vaccine market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the meningococcal vaccine market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Important points from Table of Content which is covered in this Report:
3 Disease Overview 28
3.1 Introduction 28
3.2 Etiology and Pathophysiology 29
3.2.1 Etiology 29
3.2.2 Pathophysiology 35
3.3 Symptoms 37
3.4 Prognosis 38
4 Epidemiology 39
4.1 Disease Background 39
4.2 Risk Factors and morbidities 40
4.3 Global Trends 42
4.3.1 US 43
4.3.2 5EU 44
4.3.3 Japan and Brazil 46
4.4 Forecast Methodology 47
4.4.1 Sources Used Tables 48
4.4.2 Forecast Assumptions and Methods 55
4.4.3 Sources Not Used 69
4.5 Epidemiological Forecast for IMD (2015-2025) 70
4.5.1 All IMD Combined 70
4.5.2 Laboratory-Confirmed Incident Cases of Serogroup B IMD 79
4.5.3 Laboratory-Confirmed Incident Cases of Serogroup C IMD 82
4.5.4 Laboratory-Confirmed Incident Cases of Serogroup Y IMD 84
4.5.5 Laboratory-Confirmed Incident Cases of Other Serogroup IMD 86
4.5.6 Distribution of Serogroups 88
4.5.7 US College Freshmen 90
4.6 Discussion 91
4.6.1 Epidemiological Forecast Insight 91
4.6.2 Limitations of the Analysis 93
4.6.3 Strengths of the Analysis 94
5 Disease Management 95
5.1 Meningococcal Immunization Policy 95
5.1.1 Routine Immunization Recommendations and Most Frequently Administered ……CONTINUED
List of Tables
Table 1: Symptoms of Meningococcal Disease 38
Table 2: Risk Factors and Comorbidities for IMD 41
Table 3: 8MM, Sources of Laboratory-Confirmed IMD Incidence 48
Table 4: 8MM, Sources of Laboratory-Confirmed Serogroup B IMD Incidence 49
Table 5: 8MM, Sources of Laboratory-Confirmed Serogroup C IMD Incidence 50
Table 6: 8MM, Sources of Laboratory-Confirmed Serogroup Y IMD Incidence 51
Table 7: 8MM, Sources of Laboratory-Confirmed Other Serogroup IMD Incidence (Includes Serogroups A, W, X, and All Others) 52
Table 8: 5EU, Japan, and Brazil Sources of Laboratory-Confirmed Serogroup W IMD Incidence 53
Table 9: Germany, Italy, and Brazil, Sources of Laboratory-Confirmed Serogroup A IMD Incidence 54
Table 10: College Freshmen Residing in Campus Accommodation 54
Table 11: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, Selected Years 2015-2025 71
Table 12: 8MM and Japan, Age-specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015 73
Table 13: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015 74
Table 14: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N (Row %), 2015 76
Table 15: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025 81
Table 16: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025 83
Table 17: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025 85
Table 18: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025 87
Table 19: College Freshmen in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025 91
Table 20: National Immunization Recommendation Agencies, 2016 98
Table 21: National Immunization Recommendations for Meningococcal Vaccines, 2016 100
Table 22: Most Frequently Administered Meningococcal Vaccines in the Global Markets, 2015 101 ……CONTINUED
To Purchase Complete Report@ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643855
WISE GUY RESEARCH CONSULTANTS PVT LTD
75 Arlington Street, Suite 500,
Boston, Massaachusetts – 02116
United States of America